


## **Supplementary information**


### **Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model**

Naoya Uchida<sup>1,2\*</sup>, Ulana Stasula<sup>1</sup>, Selami Demirci<sup>1</sup>, Paula Germino-Watnick<sup>1</sup>, Malikiya Hinds<sup>1</sup>, Anh Le<sup>1</sup>, Rebecca Chu<sup>1</sup>, Alexander Berg<sup>1</sup>, Xiong Liu<sup>1</sup>, Ling Su<sup>3</sup>, Xiaolin Wu<sup>3</sup>, Allen E Krouse<sup>4</sup>, N Seth Linde<sup>4</sup>, Aylin Bonifacino<sup>4</sup>, So Gun Hong<sup>4</sup>, Cynthia E Dunbar<sup>4</sup>, Leanne Lanieri<sup>5</sup>, Anjali Bhat<sup>5</sup>, Rahul Palchaudhuri<sup>5</sup>, Bindu Bennet<sup>5</sup>, Megan Hoban<sup>5</sup>, Kirk Bertelsen<sup>5</sup>, Lisa M Olson<sup>5</sup>, Robert E Donahue<sup>1</sup>, John F Tisdale<sup>1</sup>


- 1) Cellular and Molecular Therapeutics Branch, NHLBI/NIDDK, NIH, Bethesda, MD, USA
- 2) Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- 3) Genomics Technology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA
- 4) Translational Stem Cell Biology Branch, NHLBI, NIH, Bethesda, MD, USA
- 5) Magenta Therapeutics, Cambridge, Massachusetts (MA), USA




**Supplementary Figure 1. Impact of 0.2 mg/kg CD117-ADC conditioning on rhesus macaque marrow hematopoietic stem/progenitor cell content and engraftment of lentivirally-transduced autologous CD34<sup>+</sup> cells.** (A) Experimental design. Rhesus macaques (n=2), 13U047 and 12U032, were mobilized and CD34<sup>+</sup> cells ( $3.4 \pm 0.7 \times 10^6/\text{kg}$ ) collected by apheresis from the peripheral blood were purified and transduced with a lentiviral vector encoding a human  $\beta$ -globin gene (*HBB*) at MOI 50. Transduced CD34<sup>+</sup> cells (VCN  $4.7 \pm 1.2$ ) were transplanted into autologous macaques 6 days after a single intravenous dose of 0.2 mg/kg CD117-ADC. (B) Hematoxylin and eosin-stained bone marrow biopsies sampled at baseline, transplant day (day 0), and day 14 post-transplant (12U032), and shown at 20x magnification (similar observation at n=2 biologically independent animals). (C) Peripheral blood counts of granulocytes, lymphocytes, reticulocytes, and platelets in rhesus macaques beginning before CD117-ADC (day -6) and through transplantation and recovery. (D) Gene marking levels (VCN) in granulocytes and lymphocytes post-transplantation, evaluated by qPCR. LCR: locus control regions, HBBp: the *HBB* promoter. Source data are provided as a Source Data file.




**Supplementary Figure 2. Additional blood counts in rhesus macaques following conditioning.** (A-D) Blood counts (white blood cells, red blood cells, hemoglobin concentrations, and hematocrit) before and after transplantation with (A) 0.2 mg/kg CD117-ADC (13U047 and 12U032), (C) myeloablative busulfan 5.5 mg/kg x 4 days (12U018 and 12U020), and (D) 0.3-0.4 mg/kg CD117-ADC (0.3 mg/kg in ZL13 and ZJ62, 0.4 mg/kg in H635 and H96G), as well as (B) before and after CD117-ADC administration (0.2 mg/kg in JJ50, 0.3 mg/kg in ZJ10, and 0.6 mg/kg in ZI07) without autologous CD34+ cell infusion. Source data are provided as a Source Data file.



**Supplementary Figure 3. Liver and kidney tests before and after CD34+ cell transplantation in rhesus macaques.** (A-C) Liver enzymes (AST, ALT, and LDH), liver function tests (TBIL and ALB), and kidney function tests (BUN, CREA, and K) before and after transplantation with (A) 0.2 mg/kg CD117-ADC (13U047 and 12U032), (B) myeloablative busulfan (12U018 and 12U020), and (C) 0.3-0.4 mg/kg CD117-ADC (0.3 mg/kg in ZL13 and ZJ62, 0.4 mg/kg in H635 and H96G). Source data are provided as a Source Data file.



**Supplementary Figure 4. Subset analysis of peripheral blood mononuclear cells (PBMCs) in transplanted animals.** Subset analysis (CD4+ T cells, CD8+ T cells, CD20+ B cells, CD11b+CD18+ activated granulocytes, CD14+ monocytes, and CD16+CD56low natural killer (NK) cells) of PBMCs at various time points after transplantation with CD117-ADC (0.3 mg/kg in ZL13 and ZJ62, 0.4 mg/kg in H635 and H96G) and myeloablative busulfan (12U018 and 12U020). Source data are provided as a Source Data file.



**Supplementary Figure 5. Positive correlation between HbF induction levels and granulocyte VCN in rhesus macaques.** The relationship between HPLC-measured HbF ( $\gamma$ -globin) amounts and granulocyte VCN of the thEpoR/shmiR-BCL11A vector, using three timepoints for each transplanted animal (ZL13, ZJ62, H635, H96G, 12U018, and 12U020). The correlation was evaluated by  $R^2$  and p-value for coefficient of correlation.  $p=2.08e-7$ . Source data are provided as a Source Data file.


| A. Animal ID              | ZL13    | ZJ62    | H635    | H96G    | 12U018  | 12U020  |
|---------------------------|---------|---------|---------|---------|---------|---------|
| VCN                       | 0.017   | 0.124   | 0.265   | 0.060   | 1.075   | 0.282   |
| Total IS                  | 405     | 2938    | 4765    | 872     | 6368    | 4398    |
| Unique IS                 | 221     | 1073    | 3553    | 338     | 4159    | 2553    |
| Max IS counts             | 13      | 38      | 23      | 32      | 19      | 22      |
| Max IS%                   | 3.21%   | 1.29%   | 0.48%   | 3.67%   | 0.30%   | 0.50%   |
| Min IS counts             | 1       | 1       | 1       | 1       | 1       | 1       |
| UC <sub>50</sub>          | 56      | 180     | 1171    | 54      | 1087    | 604     |
| Simpson's diversity index | 0.99247 | 0.99773 | 0.99959 | 0.99200 | 0.99961 | 0.99928 |


| B. IS | ZL13               | ZJ62          | H635             | H96G           | 12U018              | 12U020           |
|-------|--------------------|---------------|------------------|----------------|---------------------|------------------|
| 1     | PHIP (3.2%)        | DACH1 (1.3%)  | CCDC59 (0.5%)    | PPP2R2A (3.7%) | CHM (0.3%)          | LINC01526 (0.5%) |
| 2     | LINC02760 (2.5%)   | GPD2 (1.2%)   | MARCHF1 (0.3%)   | SESTD1 (2.6%)  | COBLL1 (0.3%)       | SERPINI1 (0.5%)  |
| 3     | CPNE4 (2.2%)       | NDUFB4 (0.9%) | TRPM6 (0.3%)     | MIR31HG (2.2%) | LOC105370457 (0.3%) | KANSL1L (0.4%)   |
| 4     | COL8A1 (1.5%)      | FARS2 (0.9%)  | ZNF654 (0.2%)    | NDST3 (1.9%)   | RIT2 (0.3%)         | RPL13AP20 (0.4%) |
| 5     | LOC100130111(1.5%) | RBMS1 (0.8%)  | THSD7B (0.2%)    | GLRB (1.9%)    | PIK3CA (0.2%)       | C15orf41 (0.4%)  |
| 6     | PTGS2 (1.2%)       | PDGFC (0.7%)  | SYNPO2 (0.2%)    | TNIP3 (1.8%)   | MTHFD2L (0.2%)      | MCM8 (0.3%)      |
| 7     | LRP1B (1.2%)       | INTU (0.7%)   | MRPL19 (0.2%)    | HAS2 (1.7%)    | PCDH11Y (0.2%)      | PTPRQ (0.3%)     |
| 8     | MTMR2 (1.2%)       | INTU (0.7%)   | LINC02476 (0.2%) | MPEG1 (1.6%)   | NABP1 (0.2%)        | ACADL (0.3%)     |
| 9     | XIST (1.2%)        | KANSL1L(0.6%) | ABR (0.1%)       | ZNF277 (1.5%)  | CDH9 (0.2%)         | ZBTB20 (0.3%)    |
| 10    | LINC02760 (1.0%)   | PCDH9 (0.6%)  | MIB1 (0.1%)      | DDX3X (1.5%)   | LINC01478 (0.1%)    | DPYD (0.3%)      |

**Supplementary Figure 6. High diversity of lentiviral integration sites (IS) in transplanted animals.** (A) IS analysis of lentiviral vectors in granulocytes one year after transplantation with CD117-ADC (0.3 mg/kg in ZL13 and ZJ62, 0.4 mg/kg in H635 and H96G) and myeloablative busulfan (12U018 and 12U020). Diversity was evaluated by Simpson's diversity index (0 representing no diversity, and 1 representing infinite diversity). (B) Gene names of top 10 ISs along with IS percentages. VCN: average vector copy number per cell, UC<sub>50</sub>: unique clone number of top 50%. Source data are provided as a Source Data file.





**Supplementary Figure 7. Similar erythropoietin levels between before and after transplant with thEpoR/shmiR-BCL11A gene addition.** Erythropoietin levels in rhesus serum pre-transplant and 14-22 months post-transplant with thEpoR/shmiR-BCL11A gene addition following CD117-ADC conditioning (0.3 mg/kg in ZL13 and ZJ62, 0.4 mg/kg in H635 and H96G, n=4 biologically independent animals) and myeloablative busulfan conditioning (12U018 and 12U020, n=2 biologically independent animals). Data are presented as mean +/- standard deviation. Not significant (n.s.) evaluated by one-tailed paired *t*-test between pre- and post-transplant for CD117-ADC animals. Source data are provided as a Source Data file.



**Supplementary Figure 8. Gating strategies in flow cytometry.** (A) A flow cytometry panel for HbF analysis. (B) Flow cytometry panels for PBMC subset analysis, including CD4+ T cells, CD8+ T cells, CD20+ B cells, CD11b+CD18+ activated granulocytes, CD14+ monocytes, and CD16+CD56low NK cells. APC: allophycocyanin, FSC: forward scatter, PE: phycoerythrin, V450: Violet 450, R718: Red 718, FITC: fluorescein isothiocyanate, PE-Cy7: PE-Cyanine 7.